To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:
- Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)
- Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35223
- Alabama Oncology
-
-
Arizona
-
Goodyear, Arizona, United States, 85338
- City of Hope - Phoenix
-
Tucson, Arizona, United States, 85715
- Arizona Clinical Research Center (ACRC)
-
-
Arkansas
-
Springdale, Arkansas, United States, 72762
- Highlands Oncology Group
-
-
California
-
Fountain Valley, California, United States, 92708
- Compassionate Care Research Group
-
Fullerton, California, United States, 92835
- Providence Medical Foundation
-
Glendale, California, United States, 91204
- Los Angeles Cancer Network
-
Los Alamitos, California, United States, 90720
- OPN - Oncology Physician Network
-
Los Angeles, California, United States, 90034
- Kaiser Permanente Research (Southern California)
-
Sacramento, California, United States, 95817
- UC Davis
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80920
- UCHealth Memorial Hospital North
-
Greeley, Colorado, United States, 80631
- MD Anderson- North Colorado Medical Center
-
-
Florida
-
Brooksville, Florida, United States, 34613
- Advanced Cancer Treatment Centers
-
Jacksonville, Florida, United States, 32256
- Cancer Specialists North Florida
-
Miami, Florida, United States, 33140
- Mount Sinai Comprehensive Cancer Center
-
Ocala, Florida, United States, 34473
- Florida Cancer Affiliates- (Ocala Oncology - Main)
-
Orange City, Florida, United States, 32763
- Mid Florida Hematology and Oncology Center
-
Plantation, Florida, United States, 33322
- BRCR Global
-
Pompano Beach, Florida, United States, 33064
- Napa Research
-
Tamarac, Florida, United States, 33321
- Advanced Research
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96814
- Straub Benioff Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60099
- City of Hope- Chicago
-
Decatur, Illinois, United States, 62526
- Cancer Center of Decatur
-
Tinley Park, Illinois, United States, 60487
- Accellacare of Duly
-
-
Indiana
-
Dyer, Indiana, United States, 46311
- Northwest Cancer Centers
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Cancer Center of Kansas
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Baptist Health Lexington
-
Pikeville, Kentucky, United States, 41501
- Pikeville Hospital
-
-
Louisiana
-
Alexandria, Louisiana, United States, 71301
- CHRISTUS St. Frances Cabrini Cancer Center
-
Hammond, Louisiana, United States, 70433
- Pontchartrain Cancer Center
-
-
Michigan
-
Southfield, Michigan, United States, 48075
- Henry Ford Health Providence Southfield Hospital
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55101
- Health Partners Cancer Center at Regions Hospital
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- Hattiesburg Clinic Hematology/Oncology
-
-
Missouri
-
Kansas City, Missouri, United States, 64132
- MidAmerica Division Inc., c/o Research Medical Center
-
Osage Beach, Missouri, United States, 65065
- Lake Regional
-
-
Montana
-
Billings, Montana, United States, 59102
- St. Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, United States, 68106
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, United States, 89502
- Renown Health
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Center
-
-
New Jersey
-
Freehold, New Jersey, United States, 03756
- Regional Cancer Care Associates LLC RCCA
-
Neptune City, New Jersey, United States, 07753
- Jersey Shore University Medical Center
-
-
New York
-
Elmhurst, New York, United States, 11373
- Elmhurst (BRANY site)
-
Lake Success, New York, United States, 11042
- Northwell Health
-
Stony Brook, New York, United States, 11794
- Stony Brook Cancer Center
-
Williamsville, New York, United States, 14221
- Great Lakes Cancer Care (Kaleida Health)
-
-
Ohio
-
Akron, Ohio, United States, 44304
- Summa Health
-
Canton, Ohio, United States, 44708
- Cleveland Clinic Mercy Hospital
-
Canton, Ohio, United States, 44710
- Aultman Cancer Center
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
Massillon, Ohio, United States, 44646
- Tricounty Hematology and Oncology Associates
-
-
Pennsylvania
-
Wynnewood, Pennsylvania, United States, 19096
- Lankenau Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02908
- CharterCARE (Roger Williams)
-
-
Texas
-
Corpus Christi, Texas, United States, 78404
- CHRISTUS Institute for Innovation & Advanced Clinical Care
-
Edinburg, Texas, United States, 78539
- DHR Research
-
Houston, Texas, United States, 77090
- Millennium Research and Clinical Development
-
Kingwood, Texas, United States, 77339
- Lumi Research
-
Lubbock, Texas, United States, 79410
- Joe Arrington Cancer Research and Treatment Center
-
Tyler, Texas, United States, 75701
- The University of Texas Health Science Center at Tyler/HOPE Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- Utah Cancer Specialists
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Washington
-
Olympia, Washington, United States, 98502
- American Oncology Network Vista Oncology Division
-
Tacoma, Washington, United States, 98405
- Northwest Medical Specialties, PLLC
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26505
- West Virginia University Cancer Institute
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Carbone Cancer Center
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert Hospital- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Voluntary participation in clinical studies.
Male or female aged ≥ 18 years at the time of signing the ICF.
Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system).
No prior systemic therapy for ES-SCLC.
Patients who have received chemoradiotherapy for previous limited stage SCLC must be treated with curative intent and have a treatment-free interval of at least 6 months from the last course of chemotherapy, radiotherapy, or chemoradiotherapy to the diagnosis of extensive stage SCLC.
At least one measurable lesion as assessed according to RECIST 1.1 within 4 weeks prior to randomization.
Every effort should be made to provide tumor tissues for the determination of PD-L1 expression.
Prior antineoplastic therapy including Chinese medicine therapy, which has been approved as antineoplastic therapy by NMPA or its instruction has antineoplastic therapy effect, must have been ≥ 2 weeks from the first dose in this study with treatment-related AEs resolved to NCI-CTCAE Grade ≤ 1 (except for Grade 2 alopecia).
An ECOG PS score of 0 or 1.
An expected survival ≥ 12 weeks.
Subjects with prior denosumab use that can and agree to switch to bisphosphonate therapy for bone metastases starting prior to randomization and throughout treatment.
Normal major organ functions.
Female patients must meet one of the following conditions: Menopause, Surgically sterilized or of child-bearing potential, must meet the following: negative serum pregnancy test within 7 days prior to randomization and agree to use birth control methods with an annual failure rate <1% or maintain abstinence. Must not be breast-feeding.
Male patients must: agree to abstinence or take contraception measures as follows: male patients with a pregnant partner or a partner of childbearing potential must remain abstinent or use a condom or had vasectomy to prevent embryonic exposure during study treatment and for at least 6 months after the last dose of study drug. Periodic abstinence and external ejaculation are ineligible methods of contraception.
Exclusion Criteria:
Histologically or cytologically confirmed mixed SCLC.
Other active malignancies within 5 years or at the same time. Localized tumors that have been cured, such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical cancer in situ and breast cancer in situ are acceptable.
Patients who are preparing for or have received an organ or bone marrow transplant.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed regardless of drainage frequency.
Patients with known or documented active CNS metastases and/or carcinomatous meningitis at screening. However, the following subjects are allowed to be enrolled: 1) Subjects with asymptomatic brain metastases may be included but are required to receive regular brain imaging as a site of lesion. 2) Subjects with treated brain metastases which have been stable for at least 2 weeks, with no evidence of new or enlarging brain metastases, and with discontinued steroids 3 days prior to study drug administration.
Subjects with spinal cord compression that has not been treated with surgery and/or radiotherapy.
Patients with myocardial infarction within half a year before the first dose of the study drug, poorly controlled arrhythmia.
Class III to IV cardiac insufficiency according to NYHA classification.
Subject has uncontrolled or symptomatic hypercalcemia.
Subject with peripheral neuropathy ≥ Grade 2 by CTCAE.
Human immunodeficiency virus (HIV) infection, positive test for HIV antibody.
Active or latent pulmonary tuberculosis.
Subjects with previous and concurrent interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity, as judged by the investigator.
Hepatitis B or Hepatitis C or Hepatitis B and C co-infection.
Known active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.
Have received treatment with live vaccines within 28 days prior to the first administration. Subjects may receive inactivated viral vaccines for seasonal influenza but may not receive live attenuated influenza vaccines via intranasal route.
Subjects requiring treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study. However, in the absence of active autoimmune disease, subjects are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at doses equivalent to ≤ 10 mg/day of prednisone efficacy.
With any active infection requiring systemic anti-infective treatment at the time of first dose of study treatment.
Major surgery within 28 days prior to the first dose of the study drug, defined as: surgeries requiring at least 3 weeks of recovery to be able to receive treatment in this study.
Radical radiation therapy within 3 months prior to study medications. Note: Palliative radiotherapy to bone or palliative radiotherapy to superficial lesions is allowed according to local standards 14 days prior to the first dose. Radiotherapy covering more than 30% of the bone marrow area within 28 days prior to the first dose is not allowed.
The subject has previously received other antibodies/drugs against immune checkpoints, such as PD-1, PD-L1, CTLA4, etc.
Participation in any other ongoing clinical studies, or less than 14 days from the end of the previous clinical study treatment to the start of this trial.
Known history of severe allergy to any monoclonal antibody.
Known hypersensitivity to carboplatin or etoposide.
Pregnant or lactating females.
Active use of psychotropics abuse or drug abuse.
In the judgment of the investigator, the subject has any other factors that may lead to a premature discontinuation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Serplulimab + chemotherapy
Serplulimab + chemotherapy (carboplatin-etoposide) |
Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. Drug: carboplatin and etoposide chemotherapeutics |
|
Active Comparator: Atezolizumab + chemotherapy
Atezolizumab + chemotherapy (carboplatin-etoposide) |
Drug: Atezolizumab is a monoclonal antibody targeting PD-L1,developed by Roche Pharma AG. Drug: carboplatin and etoposide chemotherapeutics |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
OS
Time Frame: A period from randomization through death regardless of causality (approximately up to 24 months).
|
Overall assessment |
A period from randomization through death regardless of causality (approximately up to 24 months).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response rate (ORR)
Time Frame: approximately up to 14 months
|
Objective response rate (ORR) (assessed by independent radiology review committee [IRRC] and the investigator based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) |
approximately up to 14 months
|
|
Progression-free survival (PFS)
Time Frame: approximately up to 24 months
|
Progression-free survival (PFS) (assessed by IRRC and the investigator based on RECIST 1.1) |
approximately up to 24 months
|
|
PFS2
Time Frame: Approximately up to 24 months
|
PFS2 (assessed by the investigator based on RECIST 1.1) |
Approximately up to 24 months
|
|
Duration of response (DOR)
Time Frame: Approximately up to 24 months
|
Duration of response (DOR) (assessed by IRRC and the investigator based on RECIST 1.1) |
Approximately up to 24 months
|
|
Adverse events
Time Frame: approximately up to 24 months
|
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment. |
approximately up to 24 months
|
|
Observed concentration of HLX10 in serum
Time Frame: Approximately up to 24 months
|
Observed concentration of HLX10 in serum |
Approximately up to 24 months
|
|
Estimated PK exposure of HLX10 in serum from population pharmacokinetic analysis, expressed as mg·h/L
Time Frame: Approximately up to 24 months
|
The PK data obtained in this study will be pooled with other data from HLX10 (Serplulimab) clinical trials for further population pharmacokinetic analyses. The differences in PK exposure between American population and the obtained populations (Asian and non-Asian) will be compared through model simulation. |
Approximately up to 24 months
|
|
HLX10 anti-drug antibody (ADA)
Time Frame: Approximately up to 24 months
|
HLX10 anti-drug antibody (ADA) |
Approximately up to 24 months
|
|
Neutralizing antibody (NAb)
Time Frame: Approximately up to 24 months
|
Neutralizing antibody (NAb) positive rate |
Approximately up to 24 months
|
|
Quality of life assessment
Time Frame: Approximately up to 24 months
|
Lung cancer Quality of life assessment |
Approximately up to 24 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exploratory Endpoint
Time Frame: Approximately up to 24 months
|
Potential prognostic and predictive biomarkers, including PD-L1 expression in tumor tissue and SCLC-related blood biomarker |
Approximately up to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ASTRIDE (HLX10-005-SCLC301-E)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.